.png){kind=spacer}
Repairing Membranes to Rescue Mitochondria in Degenerative Diseases
Partnering to Develop the First Pore-Targeting Therapies
Current Partners
.png)
.png){kind=logo}
Current Opportunities
Amporin is currently seeking partners for its Alzheimer's disease (AMP-AD) and Type 2 Diabetes (AMP-DM) discovery programs prior to full preclinical testing, and is open to licensing, co-development, and other strategic partnering arrangements.
Meanwhile, Amporin is always looking for new opportunities to collaborate with CROs or academic research groups to test and validate its pore-targeting therapies. We are especially keen to work with external partners that have already established models and methods to evaluate the toxic effects of misfolded protein oligomers or pores on synthetic membranes, mitochondria, cell cultures, tissues, or animal models.
Why Partner With Us
Amporin is pursuing a bold vision: to establish toxic membrane pores as a new therapeutic target class and develop the first generation of medicines specifically designed to target toxic membrane pores across multiple degenerative diseases.
If successful, this approach could create a new category of therapies capable of addressing some of the most devastating and currently intractable diseases, including Parkinson's disease, Alzheimer's disease, Type 2 diabetes, ALS, Huntington's disease, and others. The potential impact extends far beyond any single disease and may ultimately reshape how degenerative diseases are understood and treated.
We are seeking partners who share our vision and who want to help accelerate the development of a new generation of pore-targeting therapies through research collaborations, partnerships, licensing agreements, or strategic investments.